11. Myasthenia
226 clinical trials,   172 drugs   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-000895-40-DK
(EUCTR)
28/03/201926/02/2019Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia GravisBeta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG Myasthenia Gravis
MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Salbutamol WZF 4 mg
INN or Proposed INN: Salbutamol
Other descriptive name: SALBUTAMOL SULFATE PH. EUR.
Aarhus University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 3Denmark
2ChiCTR1800017696
2016-07-012018-08-10Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia GravisEffect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis Myasthenia GravisGroup A:Magnesium Sulfate;Group B:Normal saline;The University of Hong Kong-Shenzhen HospitalNULLRecruiting1860BothGroup A:30;Group B:30;China